The blood-based supplement platform backed by Cristiano Ronaldo moves from niche optimisation to global distribution.
Bioniq, creator of personalised supplements based on blood biomarker analysis, has entered into an agreement for the sale of its assets to global nutrition company Herbalife.
Founded in 2019, Bioniq develops personalised supplement formulas using its patented product personalisation engine, an individual’s health background, and a proprietary database of biomarkers.
Bioniq’s personalised supplement formulations are designed for a broad range of individuals, from everyday wellness consumers to elite athletes.
Bioniq has built one of the largest proprietary datasets in the category, comprising over 6 million data points collected across five continents. Its patented algorithm identifies micronutrient imbalances and delivers precision daily nutrient support, complemented by one-on-one consultations and ongoing health insights.
Headquartered in London, Bioniq serves customers in more than 70 markets worldwide, including the United States, Europe, and the Middle East.
The Company is backed by prominent investors, including HV Capital and Unbound, as well as elite athletes Cristiano Ronaldo and Diogo Dalot.
Since entering the UAE in 2021, Bioniq has expanded rapidly across the Gulf region through partnerships with the Department of Culture and Tourism – Abu Dhabi and Al Borg Diagnostics in Saudi Arabia.
The $55 million purchase price will be paid over five years, including an initial payment of $10 million at closing. In addition, the transaction value includes up to $95 million of contingent payments based on future performance.
Vadim Fedotov, Founder of Bioniq, will join Herbalife’s leadership team following the completion of the transaction. Key members of the Bioniq team will also transition to Herbalife.
The acquisition will enable Bioniq’s science-driven, personalised supplementation platform to scale globally through Herbalife’s extensive infrastructure, which spans 95 markets, with over 2 million distributors and millions of customers worldwide.
Bioniq’s proprietary algorithm, formulation capabilities, and international team will be integrated into Herbalife’s ecosystem, accelerating product innovation, expanding access, and enhancing the customer experience globally.
“With a professional athletic career behind me, I created Bioniq to make health measurable, actionable, and accessible,” said Vadim Fedotov, Co-Founder and President of Bioniq.
“Our science-driven approach, proven efficacy, and sustainable business model have positioned us as a leader in personalised nutrition. Joining Herbalife allows us to accelerate our mission and bring personalised health solutions to a global audience at scale.”
“The future of health and wellness is increasingly personalised and data-driven,” said Stephan Gratziani, CEO of Herbalife.
“By combining Bioniq’s technology with our global infrastructure and Pro2col platform, we are uniquely positioned to deliver personalised nutrition to millions of consumers worldwide.“
“Throughout my career, biometrics and personalised nutrition have been central to helping me perform and compete at the highest level. As a longtime Herbalife and Bioniq user, I’ve experienced firsthand how a tailored approach to nutrition can help optimise performance,” said Cristiano Ronaldo.
“I’m delighted to see Bioniq’s personalised supplements become part of Herbalife’s expanding access to nutritional supplements, helping people take a more informed approach to their health, wellness and performance.”
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. As part of the transaction,
Herbalife also obtained a call option to acquire Bioniq LAB, a separate platform focused on small molecules and peptides.
The call option provides Herbalife with strategic flexibility to evaluate potential longer-term opportunities in this area in a disciplined and capital-efficient manner.
Bioniq’s personalised nutritional supplements are expected to be offered later this year through Herbalife independent distributors for customers in select countries in Europe and the United States, with additional markets to follow.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals.